The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:2198-2199 November 22, 2007 Number 21
NextNext

NXY-059 for the Treatment of Stroke

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Shuaib, A.
-PubMed Citation
To the Editor: Shuaib et al. (Aug. 9 issue)1 report that in the Stroke–Acute Ischemic NXY Treatment II (SAINT II) trial, NXY-059 did not improve the outcome for patients with acute stroke. The authors state that NXY-059 met all the Stroke Therapy Academic Industry Roundtable (STAIR) preclinical recommendations2 and thus question the relevance of animal models to the development of therapies for acute stroke. Analysis of the NXY-059 preclinical data reveals many deficiencies and nonadherence to the STAIR guidelines.3 Most of these studies failed to confirm adequate vascular occlusion, as exemplified by one study in which many animals had no . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.